Search

Your search keyword '"Rudà, Roberta"' showing total 508 results
Start Over Author "Rudà, Roberta" Language english
508 results on '"Rudà, Roberta"'

1. Leptomeningeal metastatic disease: new frontiers and future directions

Author

Ozair, Ahmad, Wilding, Hannah, Bhanja, Debarati, Mikolajewicz, Nicholas, Glantz, Michael, Grossman, Stuart A., Sahgal, Arjun, Le Rhun, Emilie, Weller, Michael, Weiss, Tobias, Batchelor, Tracy T., Wen, Patrick Y., Haas-Kogan, Daphne A., Khasraw, Mustafa, Rudà, Roberta, Soffietti, Riccardo, Vollmuth, Philipp, Subbiah, Vivek, Bettegowda, Chetan, Pham, Lily C., Woodworth, Graeme F., Ahluwalia, Manmeet S., and Mansouri, Alireza

Published
2025
Full Text
View/download PDF

10. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group

Author

Albert, Nathalie L, Galldiks, Norbert, Ellingson, Benjamin M, van den Bent, Martin J, Chang, Susan M, Cicone, Francesco, de Groot, John, Koh, Eng-Siew, Law, Ian, Le Rhun, Emilie, Mair, Maximilian J, Minniti, Giuseppe, Rudà, Roberta, Scott, Andrew M, Short, Susan C, Smits, Marion, Suchorska, Bogdana, Tolboom, Nelleke, Traub-Weidinger, Tatjana, Tonn, Joerg-Christian, Verger, Antoine, Weller, Michael, Wen, Patrick Y, and Preusser, Matthias

Published
2024
Full Text
View/download PDF

12. Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review

Author

Ius, Tamara, Sabatino, Giovanni, Panciani, Pier Paolo, Fontanella, Marco Maria, Rudà, Roberta, Castellano, Antonella, Barbagallo, Giuseppe Maria Vincenzo, Belotti, Francesco, Boccaletti, Riccardo, Catapano, Giuseppe, Costantino, Gabriele, Della Puppa, Alessandro, Di Meco, Francesco, Gagliardi, Filippo, Garbossa, Diego, Germanò, Antonino Francesco, Iacoangeli, Maurizio, Mortini, Pietro, Olivi, Alessandro, Pessina, Federico, Pignotti, Fabrizio, Pinna, Giampietro, Raco, Antonino, Sala, Francesco, Signorelli, Francesco, Sarubbo, Silvio, Skrap, Miran, Spena, Giannantonio, Somma, Teresa, Sturiale, Carmelo, Angileri, Filippo Flavio, and Esposito, Vincenzo

Published
2023
Full Text
View/download PDF

13. A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groups

Author

Aldape, Kenneth, Baehring, Joachim M., Bello, Lorenzo, Brat, Daniel J., Cahill, Daniel P., Chung, Caroline, Colman, Howard, Dietrich, Jorg, Drummond, Katharine, Esquenazi, Yoshua, Gerstner, Elizabeth R., Furtner, Julia, Garibotto, Valentina, Kaufmann, Timothy J., Komori, Takashi, Kotecha, Rupesh, Liau, Linda M., Lupo, Janine M., Minniti, Giuseppe, Narita, Yoshitaka, Niyazi, Maximilian, Perry, Arie, Preusser, Matthias, Rudà, Roberta, Sanai, Nader, Schmidt, Nils-Ole, Steinbach, Joachim P., Thust, Stefanie C., Tolboom, Nelleke, van der Hoorn, Anouk, van der Vaart, Thijs, Verger, Antoine, Vik-Mo, Einar Osland, Watts, Colin, Westphal, Manfred, Wesseling, Pieter, Young, Jacob S., Karschnia, Philipp, Smits, Marion, Reifenberger, Guido, Le Rhun, Emilie, Ellingson, Benjamin M, Galldiks, Norbert, Kim, Michelle M, Huse, Jason T, Schnell, Oliver, Harter, Patrick N, Mohme, Malte, von Baumgarten, Louisa, Albert, Nathalie L, Huang, Raymond Y, Mehta, Minesh P, van den Bent, Martin, Weller, Michael, Vogelbaum, Michael A, Chang, Susan M, Berger, Mitchel S, and Tonn, Joerg-Christian

Published
2023
Full Text
View/download PDF

14. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Author

Hertler, Caroline, Felsberg, Jörg, Gramatzki, Dorothee, Le Rhun, Emilie, Clarke, Jennifer, Soffietti, Riccardo, Wick, Wolfgang, Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F., Reijneveld, Jaap, Schnell, Oliver, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A., van den Bent, Martin, Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F., Phillips, Samuel, Rudà, Roberta, Wick, Antje, Tabouret, Emeline, Meyronet, David, Maurage, Claude-Alain, Rushing, Elisabeth, Rapkins, Robert, Bumes, Elisabeth, Hegi, Monika, Weyerbrock, Astrid, Aregawi, Dawit, Gonzalez-Gomez, Christian, Pellerino, Alessia, Klein, Martin, Preusser, Matthias, Bendszus, Martin, Golfinopoulos, Vassilis, von Deimling, Andreas, Gorlia, Thierry, Wen, Patrick Y., Reifenberger, Guido, and Weller, Michael

Published
2023
Full Text
View/download PDF

17. Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data

Author

Jensen, Lasse Rehné, Maier, Andrea Daniela, Lomstein, Atle, Graillon, Thomas, Hrachova, Maya, Bota, Daniela, Ruiz-Patiño, Alejandro, Arrieta, Oscar, Cardona, Andrés Felipe, Rudà, Roberta, Furtner, Julia, Roeckle, Ulrich, Clement, Paul, Preusser, Matthias, Scheie, David, Broholm, Helle, Kristensen, Bjarne Winther, Skjøth-Rasmussen, Jane, Ziebell, Morten, Munch, Tina Nørgaard, Fugleholm, Kåre, Walter, Martin A., Mathiesen, Tiit, and Mirian, Christian

Published
2022
Full Text
View/download PDF

19. Financial challenges of being on long-term, high-cost medications.

Author

Elshiekh, Cleopatra, Rudà, Roberta, Cliff, Edward R Scheffer, Gany, Francesca, and Budhu, Joshua A

Subjects
*ECONOMIC impact, *QUALITY of life, *PATIENT compliance, *SOCIAL determinants of health, *ISOCITRATE dehydrogenase, *DRUG prices
Abstract

The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this targeted therapy raises significant financial concerns. High costs of targeted cancer therapies, often exceeding $150 000 annually, contribute to financial toxicity, characterized by medical debt, income loss, and psychological stress, and place stress on health systems. This review analyzes the drug approval and pricing mechanisms in various countries and their impact on healthcare costs and patient access, focusing specifically on the impacts in neuro-oncology. The United States employs a market-driven approach resulting in higher drug prices, while most countries, such as the United Kingdom, Germany, France, Italy, Japan, South Africa, and Brazil, use negotiated pricing and health technology assessment to manage costs. The financial burden of expensive medications affects patient adherence and quality of life, with many cancer patients facing substantial out-of-pocket expenses and potential treatment abandonment, and many more unable to access these drugs altogether. Vorasidenib's introduction, while potentially improving patient outcomes, may exacerbate financial toxicity unless mitigated by patient access programs and cost-management strategies. As neuro-oncology treatment paradigms evolve, understanding the economic implications of new therapies is essential to ensure equitable access and optimize patient care. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

20. Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.

Author

Lim-Fat, Mary Jane, Bennett, Julie, Ostrom, Quinn, Touat, Mehdi, Franceschi, Enrico, Schulte, Jessica, Bindra, Ranjit S, Fangusaro, Jason, Dhall, Girish, Nicholson, James, Jackson, Sadhana, Davidson, Tom Belle, Calaminus, Gabriele, Robinson, Giles, Whittle, James R, Hau, Peter, Ramaswamy, Vijay, Pajtler, Kristian W, Rudà, Roberta, and Foreman, Nicholas K

Published
2025
Full Text
View/download PDF

21. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience

Author

Diamanti, Luca, Picca, Alberto, Bini, Paola, Gastaldi, Matteo, Alfonsi, Enrico, Pichiecchio, Anna, Rota, Eugenia, Rudà, Roberta, Bruno, Francesco, Villani, Veronica, Galiè, Edvina, Vogrig, Alberto, Valente, Mariarosaria, Zoccarato, Marco, Poretto, Valentina, Giometto, Bruno, Cimminiello, Carolina, Del Vecchio, Michele, and Marchioni, Enrico

Published
2022
Full Text
View/download PDF

23. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Author

van den Bent, Martin J, Tesileanu, C Mircea S, Wick, Wolfgang, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Erridge, Sarah, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean Français, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Caparrotti, Francesca, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Lim, Elizabeth, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, de Heer, Iris, Aldape, Kenneth, Jenkins, Robert B, Dubbink, Hendrikus Jan, Kros, Johan M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, French, Pim, and Baumert, Brigitta G

Published
2021
Full Text
View/download PDF

25. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

Author

Tesileanu, C. Mircea S., Vallentgoed, Wies R., Sanson, Marc, Taal, Walter, Clement, Paul M., Wick, Wolfgang, Brandes, Alba Ariela, Baurain, Jean Francais, Chinot, Olivier L., Wheeler, Helen, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H., Caparrotti, Francesca, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Lim, Elizabeth, de Vos, Filip, Mulholland, Paul J., Taphoorn, Martin J. B., de Heer, Iris, Hoogstrate, Youri, de Wit, Maurice, Boggiani, Lorenzo, Venneker, Sanne, Oosting, Jan, Bovée, Judith V. M. G., Erridge, Sara, Vogelbaum, Michael A., Nowak, Anna K., Mason, Warren P., Kros, Johan M., Wesseling, Pieter, Aldape, Ken, Jenkins, Robert B., Dubbink, Hendrikus J., Baumert, Brigitta, Golfinopoulos, Vassilis, Gorlia, Thierry, van den Bent, Martin, and French, Pim J.

Published
2021
Full Text
View/download PDF

27. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Author

Weller, Michael, van den Bent, Martin, Preusser, Matthias, Le Rhun, Emilie, Tonn, Jörg C., Minniti, Giuseppe, Bendszus, Martin, Balana, Carmen, Chinot, Olivier, Dirven, Linda, French, Pim, Hegi, Monika E., Jakola, Asgeir S., Platten, Michael, Roth, Patrick, Rudà, Roberta, Short, Susan, Smits, Marion, Taphoorn, Martin J. B., von Deimling, Andreas, Westphal, Manfred, Soffietti, Riccardo, Reifenberger, Guido, and Wick, Wolfgang

Published
2021
Full Text
View/download PDF

28. Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian Association of Neuro-Oncology) and SIN (Italian Society of Neurology)

Author

Gaviani, Paola, Simonetti, Giorgia, Rudà, Roberta, Franchino, Federica, Lombardi, Giuseppe, Possanzini, Marco, Squintu, Sara, Villani, Veronica, Teriaca, Mariaausilia, Cavallieri, Francesco, Caffo, Maria, Salmaggi, Andrea, Bianco, Andrea, Anghileri, Elena, Farinotti, Mariangela, Tramacere, Irene, and Silvani, Antonio

Published
2021
Full Text
View/download PDF

35. Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Author

Weller, Michael, van den Bent, Martin, Preusser, Matthias, Le Rhun, Emilie, Tonn, Jörg C., Minniti, Giuseppe, Bendszus, Martin, Balana, Carmen, Chinot, Olivier, Dirven, Linda, French, Pim, Hegi, Monika E., Jakola, Asgeir S., Platten, Michael, Roth, Patrick, Rudà, Roberta, Short, Susan, Smits, Marion, Taphoorn, Martin J. B., von Deimling, Andreas, Westphal, Manfred, Soffietti, Riccardo, Reifenberger, Guido, and Wick, Wolfgang

Published
2022
Full Text
View/download PDF

36. Inequalities in access to neuro-oncology supportive care and rehabilitation: A survey of healthcare professionals' perspectives.

Author

Boele, Florien, Rosenlund, Lena, Nordentoft, Sara, Melhuish, Sara, Nicklin, Emma, Rydén, Isabelle, Williamson, Aoife, Donders-Kamphuis, Marike, Preusser, Matthias, Rhun, Emilie Le, Kiesel, Barbara, Minniti, Giuseppe, Furtner, Julia, Dirven, Linda, Taphoorn, Martin, Galldiks, Norbert, Rudà, Roberta, Chalmers, Anthony, Short, Susan C, and Piil, Karin

Subjects
MEDICAL personnel, PHYSICIANS, NEUROREHABILITATION, PSYCHO-oncology, ONCOLOGY nursing, REHABILITATION, HEALTH equity, BRAIN cancer
Abstract

Background Neuro-oncology patients and caregivers should have equitable access to rehabilitation, supportive-, and palliative care. To investigate existing issues and potential solutions, we surveyed neuro-oncology professionals to explore current barriers and facilitators to screening patients' needs and referral to services. Methods Members of the European Association of Neuro-Oncology and the European Organisation for Research and Treatment of Cancer Brain Tumor Group (EORTC-BTG) were invited to complete a 39-item online questionnaire covering the availability of services, screening, and referral practice. Responses were analyzed descriptively; associations between sociodemographic/clinical variables and screening/referral practice were explored. Results In total, 103 participants completed the survey (67% women and 57% medical doctors). Fifteen professions from 23 countries were represented. Various rehabilitation, supportive-, and palliative care services were available yet rated "inadequate" by 21–37% of participants. Most respondents with a clinical role (n  = 94) declare to screen (78%) and to refer (83%) their patients routinely for physical/cognitive/emotional issues. Survey completers (n  = 103) indicated the main reasons for not screening/referring were (1) lack of suitable referral options (50%); (2) shortage of healthcare professionals (48%); and (3) long waiting lists (42%). To improve service provision, respondents suggested there is a need for education about neuro-oncology-specific issues (75%), improving the availability of services (65%) and staff (64%), developing international guidelines (64%), and strengthening the existing evidence-base for rehabilitation (60%). Conclusions Detecting and managing neuro-oncology patients' and caregivers' rehabilitation, supportive,- and palliative care needs can be improved. Better international collaboration can help address healthcare disparities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.

Author

Nayak, Lakshmi, Bettegowda, Chetan, Scherer, Florian, Galldiks, Norbert, Ahluwalia, Manmeet, Baraniskin, Alexander, Baumgarten, Louisa von, Bromberg, Jacoline E C, Ferreri, Andrés J M, Grommes, Christian, Hoang-Xuan, Khê, Kühn, Julia, Rubenstein, James L, Rudà, Roberta, Weller, Michael, Chang, Susan M, Bent, Martin J van den, Wen, Patrick Y, and Soffietti, Riccardo

Published
2024
Full Text
View/download PDF

40. Prevention of Brain Metastases: A New Frontier.

Author

Pellerino, Alessia, Davidson, Tara Marie, Bellur, Shreyas S., Ahluwalia, Manmeet S., Tawbi, Hussein, Rudà, Roberta, and Soffietti, Riccardo

Subjects
BRAIN tumor risk factors, MELANOMA, TRASTUZUMAB, BREAST tumors, METASTASIS, LUNG tumors, BRAIN tumors
Abstract

Simple Summary: This review discusses the topic of prevention of brain metastases from the most frequent solid tumor types, i.e., lung cancer, breast cancer and melanoma. Within each tumor type, the issues of screening in asymptomatic patients, prophylactic strategies with radiation and secondary chemoprevention with targeted agents are discussed. This review discusses the topic of prevention of brain metastases from the most frequent solid tumor types, i.e., lung cancer, breast cancer and melanoma. Within each tumor type, the risk of brain metastasis is related to disease status and molecular subtype (i.e., EGFR-mutant non-small cell lung cancer, HER2-positive and triple-negative breast cancer, BRAF and NRAF-mutant melanoma). Prophylactic cranial irradiation is the standard of care in patients in small cell lung cancer responsive to chemotherapy but at the price of late neurocognitive decline. More recently, several molecular agents with the capability to target molecular alterations driving tumor growth have proven as effective in the prevention of secondary relapse into the brain in clinical trials. This is the case for EGFR-mutant or ALK-rearranged non-small cell lung cancer inhibitors, tucatinib and trastuzumab–deruxtecan for HER2-positive breast cancer and BRAF inhibitors for melanoma. The need for screening with an MRI in asymptomatic patients at risk of brain metastases is emphasized. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Author

Lombardi, Giuseppe, De Salvo, Gian Luca, Brandes, Alba Ariela, Eoli, Marica, Rudà, Roberta, Faedi, Marina, Lolli, Ivan, Pace, Andrea, Daniele, Bruno, Pasqualetti, Francesco, Rizzato, Simona, Bellu, Luisa, Pambuku, Ardi, Farina, Miriam, Magni, Giovanna, Indraccolo, Stefano, Gardiman, Marina Paola, Soffietti, Riccardo, and Zagonel, Vittorina

Published
2019
Full Text
View/download PDF

45. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Author

van den Bent, Martin J, Baumert, Brigitta, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Sanson, Marc, Brandes, Alba Ariela, Clement, Paul M, Baurain, Jean Francais, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Brachman, David G, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Reijneveld, Jaap, Enting, Roelien H, Weber, Damien C, Lesimple, Thierry, Clenton, Susan, Gijtenbeek, Anja, Pascoe, Sarah, Herrlinger, Ulrich, Hau, Peter, Dhermain, Frederic, van Heuvel, Irene, Stupp, Roger, Aldape, Ken, Jenkins, Robert B, Dubbink, Hendrikus Jan, Dinjens, Winand N M, Wesseling, Pieter, Nuyens, Sarah, Golfinopoulos, Vassilis, Gorlia, Thierry, Wick, Wolfgang, and Kros, Johan M

Published
2017
Full Text
View/download PDF

47. EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors

Author

Rudà, Roberta, Capper, David, Waldman, Adam D, Pallud, Johan, Minniti, Giuseppe, Kaley, Thomas J, Bouffet, Eric, Tabatabai, Ghazaleh, Aronica, Eleonora, Jakola, Asgeir S, Pfister, Stefan M, Schiff, David, Lassman, Andrew B, Solomon, David A, Soffietti, Riccardo, Weller, Michael, Preusser, Matthias, Idbaih, Ahmed, Wen, Patrick Y, van den Bent, Martin J, Neurology, Pathology, ANS - Cellular & Molecular Mechanisms, and University of Zurich

Subjects
Proto-Oncogene Proteins B-raf, Cancer Research, Adolescent, Brain Neoplasms, neuronal tumors, 610 Medicine & health, Glioma, Astrocytoma, 10040 Clinic for Neurology, Young Adult, Oncology, SDG 3 - Good Health and Well-being, circumscribed astrocytic gliomas, glioneuronal tumors, guideline, Humans, Neurology (clinical), Child, Ganglioglioma
Abstract

In the new WHO 2021 Classification of CNS Tumors the chapter “Circumscribed astrocytic gliomas, glioneuronal and neuronal tumors” encompasses several different rare tumor entities, which occur more frequently in children, adolescents, and young adults. The Task Force has reviewed the evidence of diagnostic and therapeutic interventions, which is low particularly for adult patients, and draw recommendations accordingly. Tumor diagnosis, based on WHO 2021, is primarily performed using conventional histological techniques; however, a molecular workup is important for differential diagnosis, in particular, DNA methylation profiling for the definitive classification of histologically unresolved cases. Molecular factors are increasing of prognostic and predictive importance. MRI finding are non-specific, but for some tumors are characteristic and suggestive. Gross total resection, when feasible, is the most important treatment in terms of prolonging survival and achieving long-term seizure control. Conformal radiotherapy should be considered in grade 3 and incompletely resected grade 2 tumors. In recurrent tumors reoperation and radiotherapy, including stereotactic radiotherapy, can be useful. Targeted therapies may be used in selected patients: BRAF and MEK inhibitors in pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and gangliogliomas when BRAF altered, and mTOR inhibitor everolimus in subependymal giant cells astrocytomas. Sequencing to identify molecular targets is advocated for diagnostic clarification and to direct potential targeted therapies.

Published
2022
Full Text
View/download PDF

48. The Impact of Lateral Ventricular Opening in the Resection of Newly Diagnosed High-Grade Gliomas: A Single Center Experience.

Author

Cofano, Fabio, Bianconi, Andrea, De Marco, Raffaele, Consoli, Elena, Zeppa, Pietro, Bruno, Francesco, Pellerino, Alessia, Panico, Flavio, Salvati, Luca Francesco, Rizzo, Francesca, Morello, Alberto, Rudà, Roberta, Morana, Giovanni, Melcarne, Antonio, and Garbossa, Diego

Subjects
GLIOMAS, HYDROCEPHALUS, CEREBROSPINAL fluid leak, CEREBRAL ventricles, RESEARCH evaluation, RETROSPECTIVE studies, DESCRIPTIVE statistics, SURGICAL complications, RESEARCH, CONFIDENCE intervals, PROGRESSION-free survival, BRAIN tumors, OVERALL survival
Abstract

Simple Summary: This retrospective study investigates the validity of lateral ventricle opening during high-grade glioma (HGG) surgery, contributing to the literature by addressing its relationship with postoperative complications in a large cohort of newly diagnosed patients with HGG. The approach of dividing patients into groups with and without lateral ventricle opening enhances the study's internal validity, allowing for a direct comparison between the two conditions. The analysis of complications, including subependymal dissemination and multifocal progression, contributes to understanding associated side effects. Furthermore, the conclusion that lateral ventricle opening does not significantly increase the risks of dissemination, hydrocephalus or cerebrospinal fluid leakage suggests practical implications for surgery. Given the importance of maximizing resection for prognosis in patients with HGG and the potential risks associated with ventricle opening, this study aimed to assess the actual increase in post-surgical complications related to lateral ventricle opening and its influence on OS and PFS. A retrospective study was conducted on newly diagnosed HGG, dividing the patients into two groups according to whether the lateral ventricle was opened (69 patients) or not opened (311 patients). PFS, OS, subependymal dissemination, distant parenchymal recurrences, the development of hydrocephalus and CSF leak were considered outcome measures. A cohort of 380 patients (154 females (40.5%) and 226 males (59.5%)) was involved in the study (median age 61 years). The PFS averaged 10.9 months (±13.3 SD), and OS averaged 16.6 months (± 16.3 SD). Among complications, subependymal dissemination was registered in 15 cases (3.9%), multifocal and multicentric progression in 56 cases (14.7%), leptomeningeal dissemination in 12 (3.2%) and hydrocephalus in 8 (2.1%). These occurrences could not be clearly justified by ventricular opening. The act of opening the lateral ventricles itself does not carry an elevated risk of dissemination, hydrocephalus or cerebrospinal fluid (CSF) leak. Therefore, if necessary, it should be pursued to achieve radical removal of the disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results